The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
Open accessAbstract
We evaluated neoadjuvant ipilimumab in patients with surgically operable regionally advanced melanoma in order to define markers of activity in the blood and tumor as assessed at baseline (before ipilimumab) and early on-treatment. Patients were treated with ipilimumab (10 mg/kg intravenously every 3 weeks ×2 doses) bracketing surgery. Tumor and blood biospecimens were obtained at baseline and at surgery. Flow cytometry and immunohistochemistry for select biomarkers were performed. Thirty five patients were enrolled; IIIB (3; N2b), IIIC (32; N2c, N3), IV (2). Worst toxicities included Grade 3 diarrhea/colitis (5; 14%), hepatitis (2; 6%), rash (1; 3%), elevated lipase (3; 9%). Median follow up was 18 months: among 33 evaluable patients, median progression free survival (PFS) was 11 months, 95% CI (6.2-19.2). There was a significant decrease in circulating myeloid derived suppressor cells (MDSC). Greater decrease in circulating monocyte gate MDSC Lin1-/HLA-DR-/CD33⁺/CD11b⁺ was associated with improved PFS (p = 0.03). There was a significant increase in circulating regulatory T cells (Treg; CD4⁺CD25hi⁺Foxp3⁺) that, unexpectedly, was associated with improved PFS (HR = 0.57; p = 0.034). Baseline evidence of fully activated type I CD4⁺ and CD8⁺ antigen-specific T cell immunity against cancer-testis (NY-ESO-1) and melanocytic lineage (MART-1, gp100) antigens was detected and was significantly potentiated after ipilimumab. In tumor, there was a significant increase in CD8⁺ T cells after ipilimumab (p = 0.02). Ipilimumab induced increased tumor infiltration by fully activated (CD69⁺) CD3⁺/CD4⁺ and CD3⁺/CD8⁺ T cells with evidence of induction/potentiation of memory T cells (CD45RO⁺). The change in Treg observed within the tumor showed an inverse relationship with clinical benefit and greater decrease in tumor MDSC subset Lin1-/HLA-DR-/CD33⁺/CD11b⁺ was associated with improved PFS at one year. Neoadjuvant evaluation revealed a significant immunomodulating role for ipilimumab on Treg, MDSC and effector T cells in the circulation and tumor microenvironment that warrants further pursuit in the quest for optimizing melanoma immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Grossman, H. B., Natale, R. B., Tangen, C. M., Speights, V. O., Vogelzang, N. J., Trump, D. L., White, R. W. D., Sarosdy, M. F., Wood, D. P., Raghavan, D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022148 · Cited by 2,668
Fisher, B., Brown, A., Mamounas, E., Wieand, S., Robidoux, A., Margolese, R. G., Cruz, A. B., Fisher, E. R., Wickerham, D. L., Wolmark, N., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2483 · Cited by 1,801
(2002) · The Lancet · doi:10.1016/s0140-6736(02)08651-8 · Cited by 1,459
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Zea, A. H., Rodriguez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D., Quiceno, D., Youmans, A., O'Neill, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4505 · Cited by 851
Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2883 · Cited by 788
Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., & Rivoltini, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5829 · Cited by 647
Myeloid-derived suppressor cell heterogeneity and subset definition
Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., & Bronte, V. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.021 · Cited by 630
Erdag, G., Schaefer, J. T., Smolkin, M. E., Deacon, D. H., Shea, S. M., Dengel, L. T., Patterson, J. W., & Slingluff, C. L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3218 · Cited by 590
Gabitass, R. F., Annels, N. E., Stocken, D. D., Pandha, H. A., & Middleton, G. W. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1028-0 · Cited by 575
Youn, J., & Gabrilovich, D. I. (2010) · European Journal of Immunology · doi:10.1002/eji.201040895 · Cited by 568
Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534 · cited 1×
“Hamid, et al reported a significant association between high baseline tumor FOXP3 expression by IHC and improved clinical outcome after ipilimumab treatment for metastatic melanoma supporting a role for ipilimumab in modulating intra-tumoral Treg [31].”
BackgroundBalch, C. M., Urist, M. M., Karakousis, C. P., Smith, T. J., Temple, W. J., Drzewiecki, K., Jewell, W. R., Bartolucci, A. A., Mihm, M. C., Barnhill, R., et al. (1993) · Annals of Surgery · doi:10.1097/00000658-199309000-00005 · Cited by 525
Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0569 · Cited by 460
Balch, C. M., Soong, S.-J., Smith, T., Ross, M. I., Urist, M. M., Karakousis, C. P., Temple, W. J., Mihm, M. C., Barnhill, R. L., Jewell, W. R., et al. (2001) · Annals of Surgical Oncology · doi:10.1007/s10434-001-0101-x · Cited by 406
Mandapathil, M., Hilldorfer, B., Szczepanski, M. J., Czystowska, M., Szajnik, M., Ren, J., Lang, S., Jackson, E. K., Gorelik, E., & Whiteside, T. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.047423 · Cited by 390
Poschke, I., Mougiakakos, D., Hansson, J., Masucci, G. V., & Kiessling, R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3767 · Cited by 382
DiLillo, D. J., Yanaba, K., & Tedder, T. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903009 · Cited by 359
IL4Rα+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients
Mandruzzato, S., Solito, S., Falisi, E., Francescato, S., Chiarion-Sileni, V., Mocellin, S., Zanon, A., Rossi, C. R., Nitti, D., Bronte, V., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803831 · Cited by 304
Nagaraj, S., Youn, J.-I., Weber, H., Iclozan, C., Lu, L., Cotter, M. J., Meyer, C., Becerra, C. R., Fishman, M., Antonia, S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3272 · Cited by 286
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
Filipazzi, P., Huber, V., & Rivoltini, L. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1161-9 · Cited by 243
Karakousis, C. P., Balch, C. M., Urist, M. M., Ross, M. M., Smith, T. J., & Bartolucci, A. A. (1996) · Annals of Surgical Oncology · doi:10.1007/bf02305762 · Cited by 239
Tarhini, A. (2013) · Scientifica · doi:10.1155/2013/857519 · Cited by 236
Self-citationPalucka, A. K., Ueno, H., Connolly, J., Kerneis-Norvell, F., Blanck, J.-P., Johnston, D. A., Fay, J., & Banchereau, J. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211309.90621.8b · Cited by 234
Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma
Vence, L., Palucka, A. K., Fay, J. W., Ito, T., Liu, Y.-J., Banchereau, J., & Ueno, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710557105 · Cited by 175
Tarhini, A. A., Cherian, J., Moschos, S. J., Tawbi, H. A., Shuai, Y., Gooding, W. E., Sander, C., & Kirkwood, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.5394 · Cited by 160
Self-citationMenard, C., Ghiringhelli, F., Roux, S., Chaput, N., Mateus, C., Grohmann, U., Caillat‐Zucman, S., Zitvogel, L., & Robert, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4797 · Cited by 111
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression
Whiteside, T. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.482207 · Cited by 95
Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer
García‐Estévez, L., & Gradishar, W. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0133 · Cited by 94
Tarhini, A. A., Butterfield, L. H., Shuai, Y., Gooding, W. E., Kaliński, P., & Kirkwood, J. M. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318272569b · Cited by 62
Self-citationRao, U. N. M., Lee, S. J., Luo, W., Mihm, M. C., & Kirkwood, J. M. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcptxmefovywda6 · Cited by 56
Self-citation
Cited by
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0577 · Cited by 894
Metadata
- Authors
- Tarhini, A. A., Edington, H., Butterfield, L. H., Lin, Y., Shuai, Y., Tawbi, H., Sander, C., Yin, Y., Holtzman, M., Johnson, J., Rao, U. N. M., & Kirkwood, J. M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-03
- Volume
- 9
- Issue
- 2
- Pages
- e87705
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2055901890
- Cited by
- 310
- References
- 37
- FWCI
- 16.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.